Syncona Partners LLP is a venture capital firm based in London, specializing in investments within the healthcare sector. Established in 2012, it focuses on supporting and building companies in life sciences, particularly in areas such as gene therapy, targeted cell therapy, and advanced diagnostics. Syncona aims to partner with innovative leaders in science to create globally competitive businesses that deliver transformative treatments for patients with high unmet medical needs. The firm invests globally, typically committing between £1 million and £20 million per company, and operates both as a majority investor and alongside other investors. With strong backing from The Wellcome Trust and Cancer Research UK, Syncona is committed to generating superior returns for shareholders while also contributing to charitable causes through annual donations based on its net asset value.
Purespring Therapeutics is an innovative company dedicated to developing gene therapies for kidney diseases, with a strong emphasis on podocytes, the specialized cells in the kidneys. As one of the pioneers in utilizing AAV gene therapy for renal conditions, Purespring aims to address significant unmet medical needs in this challenging area of healthcare. The company has established an in-vivo functional screening platform designed to identify protective factors that could be beneficial across a range of kidney diseases, while also exploring applications for gene therapy in cardiovascular disorders. Through its focused approach, Purespring is positioned to make a meaningful impact in the treatment of renal conditions.
Resolution Therapeutics
Series B in 2024
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapies aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the potential of macrophages as therapeutic agents for conditions such as liver cirrhosis. Through its research and innovation, Resolution Therapeutics seeks to address the significant unmet regenerative therapeutic needs associated with chronic liver conditions, contributing to advancements in medical treatments for these ailments.
iOnctura
Series B in 2024
iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.
Freeline Therapeutics
Acquisition in 2023
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.
SwanBio Therapeutics
Venture Round in 2023
SwanBio Therapeutics is dedicated to developing therapeutic technologies aimed at treating neurological diseases. The company specializes in creating and commercializing genetically defined therapies tailored for neurological disorders. Its innovative approach seeks to provide significant clinical efficacy, particularly for conditions such as Adrenomyeloneuropathy (AMN) and other related diseases, thereby supporting healthcare organizations in their efforts to improve patient outcomes.
Beacon Therapeutics
Series A in 2023
Beacon Therapeutics is a clinical-stage biotechnology company that specializes in ophthalmic gene therapy aimed at restoring and improving vision for patients with rare retinal diseases that can lead to blindness. Utilizing a proprietary gene therapy platform, the company develops innovative genetic therapies tailored for individuals suffering from rare and debilitating conditions, particularly in the fields of ophthalmology and pulmonary medicine. Through its work, Beacon Therapeutics seeks to transform the lives of patients facing severe health challenges by offering potential breakthrough treatments.
Mosaic Therapeutics
Series A in 2023
Mosaic Therapeutics is reshaping the interface of computational and experimental medicine to power new medicines for patients.
AGTC
Acquisition in 2022
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company focused on developing innovative genetic therapies for patients with rare and debilitating diseases. The company has advanced product candidates in ophthalmology, including treatments for X-linked retinitis pigmentosa and achromatopsia, with the former having completed Phase I/II trials and the latter currently in the same stage. Additionally, AGTC is working on an optogenetic therapy for patients with advanced retinal diseases. Beyond ophthalmology, the company has initiated preclinical programs targeting otology and central nervous system disorders, including frontotemporal dementia, amyotrophic lateral sclerosis, and adrenoleukodystrophy. AGTC employs gene therapy techniques to replace defective genes with functional ones, aiming to provide long-lasting treatment solutions through single injections. Established in 1999 and headquartered in Alachua, Florida, the company collaborates with various academic and industry partners to enhance its research and development efforts.
SwanBio Therapeutics
Series B in 2022
SwanBio Therapeutics is dedicated to developing therapeutic technologies aimed at treating neurological diseases. The company specializes in creating and commercializing genetically defined therapies tailored for neurological disorders. Its innovative approach seeks to provide significant clinical efficacy, particularly for conditions such as Adrenomyeloneuropathy (AMN) and other related diseases, thereby supporting healthcare organizations in their efforts to improve patient outcomes.
OMass Therapeutics
Series B in 2022
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.
Resolution Therapeutics
Series A in 2022
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapies aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the potential of macrophages as therapeutic agents for conditions such as liver cirrhosis. Through its research and innovation, Resolution Therapeutics seeks to address the significant unmet regenerative therapeutic needs associated with chronic liver conditions, contributing to advancements in medical treatments for these ailments.
Freeline Therapeutics
Post in 2022
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.
Anaveon
Series B in 2021
Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.
Quell Therapeutics
Series B in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Clade Therapeutics
Series A in 2021
Clade Therapeutics is a biopharmaceutical company established in 2020 and based in Cambridge, Massachusetts. The company specializes in the discovery and development of scalable, off-the-shelf stem cell-based medicines aimed at treating a variety of diseases, including cancer and autoimmune disorders. Clade Therapeutics integrates advancements in stem cell biology, immunology, regenerative medicine, and gene editing to create next-generation cell therapies. Its initial focus centers on developing therapies utilizing T cells and other immune cells, thereby enhancing the accessibility and effectiveness of stem cell-derived treatments for patients.
Gyroscope
Series C in 2021
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Quell Therapeutics
Series A in 2021
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Resolution Therapeutics
Series A in 2020
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapies aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the potential of macrophages as therapeutic agents for conditions such as liver cirrhosis. Through its research and innovation, Resolution Therapeutics seeks to address the significant unmet regenerative therapeutic needs associated with chronic liver conditions, contributing to advancements in medical treatments for these ailments.
Purespring
Series A in 2020
Purespring Therapeutics is an innovative company dedicated to developing gene therapies for kidney diseases, with a strong emphasis on podocytes, the specialized cells in the kidneys. As one of the pioneers in utilizing AAV gene therapy for renal conditions, Purespring aims to address significant unmet medical needs in this challenging area of healthcare. The company has established an in-vivo functional screening platform designed to identify protective factors that could be beneficial across a range of kidney diseases, while also exploring applications for gene therapy in cardiovascular disorders. Through its focused approach, Purespring is positioned to make a meaningful impact in the treatment of renal conditions.
Achilles Therapeutics
Series C in 2020
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Neogene Therapeutics
Series A in 2020
Neogene Therapeutics, Inc. is a biotechnology company based in New York, founded in 2018, that focuses on developing T cell therapies for cancer treatment. The company specializes in creating personalized engineered T cells that target neo-antigens, which are mutated proteins present in cancer cells due to DNA mutations. By leveraging advanced technologies, Neogene isolates T cell receptor (TCR) genes specific to these neo-antigens from tumor biopsies routinely collected from patients. This process utilizes high-sensitivity DNA sequencing and genetic screening to identify TCRs that can effectively recognize and attack cancer cells. Neogene's innovative approach aims to enhance the precision and efficacy of cancer therapies, offering improved treatment options for patients facing a broad spectrum of cancers.
SwanBio Therapeutics
Series A in 2020
SwanBio Therapeutics is dedicated to developing therapeutic technologies aimed at treating neurological diseases. The company specializes in creating and commercializing genetically defined therapies tailored for neurological disorders. Its innovative approach seeks to provide significant clinical efficacy, particularly for conditions such as Adrenomyeloneuropathy (AMN) and other related diseases, thereby supporting healthcare organizations in their efforts to improve patient outcomes.
OMass Therapeutics
Series A in 2020
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.
Freeline Therapeutics
Series C in 2019
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.
Azeria Therapeutics
Series B in 2019
Azeria Therapeutics Limited is a drug discovery company based in Cambridge, United Kingdom, founded in 2017. The company focuses on developing treatments for patients suffering from hormone-resistant breast and prostate cancer, addressing significant unmet clinical needs in this area. Azeria specializes in a pipeline of small molecules that selectively inhibit pioneer factors, which are crucial in the development and progression of these cancers. By targeting these factors, the company aims to provide more effective treatment options for healthcare professionals managing various cancer types, thereby improving outcomes for patients.
Gyroscope
Series B in 2019
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Achilles Therapeutics
Series B in 2019
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Quell Therapeutics
Series A in 2019
Quell's vision is to become a leading engineered Treg cell therapy company. The company will seek to develop next generation engineered T-regulatory cell (Treg) therapies for a range of solid organ transplant and autoimmune conditions. Quell has been founded by Syncona in partnership with six leading experts in the Treg field, cell engineering, solid organ transplantation and autoimmune diseases: Giovanna Lombardi, Professor of Human Transplant Immunology at Kings College London (KCL), Alberto Sanchez-Fueyo, Professor of Hepatology in the Institute of Liver Studies at KCL, Hans Stauss, Professor of Tumour Immunology and Director of the Institute of Immunity and Transplantation at University College London (UCL), Emma Morris, Professor of Clinical Cell & Gene Therapy and Inflammation, Immunity and Immunotherapeutics Theme Director, National Institute for Health Research University College London Hospitals Biomedical Research Centre, Marc Martinez-Llordella, Senior Lecturer in the Institute of Liver Studies at KCL and Elmar Jaeckel, Co-Leader Liver Transplant program MHH, Group Leader "Immune tolerance" in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School.
Anaveon
Series A in 2019
Anaveon AG is a biopharmaceutical company based in Bottmingen, Switzerland, founded in 2017. The company specializes in developing biologics that modulate cytokine functions, particularly focusing on next-generation IL-2 complexes. These complexes selectively enhance effector T cell functions, acting as effective immune adjuvants with a broad therapeutic window. Anaveon's innovative compounds demonstrate significant preclinical efficacy against cancer, both as standalone treatments and in combination with other therapies. The company's mission is to transform cytokines into life-saving treatments for patients suffering from various diseases characterized by immune system dysfunction. Through its targeted approach, Anaveon aims to provide substantial therapeutic benefits to cancer patients and others affected by immune pathology.
Orbit Biomedical
Seed Round in 2019
Orbit Biomedical Limited is a retinal gene therapy company focused on developing innovative surgical devices and procedures for retinal conditions. Founded in 2018 and based in Stevenage, United Kingdom, with an additional location in Ambler, Pennsylvania, the company aims to enhance the precision, safety, and consistency of therapeutic delivery. Orbit Biomedical designs a comprehensive training process for surgeons and clinical staff, incorporating various learning modalities to ensure effective education. By transforming the surgical delivery of gene and cell therapies, the company seeks to establish a new standard in the field, enabling safe and efficient one-time treatments for patients suffering from chronic diseases.
OMass Therapeutics
Series A in 2018
OMass Therapeutics Limited is a biotechnology company based in Oxford, United Kingdom, established in 2016. The company specializes in drug discovery, utilizing structural mass spectrometry technology to develop innovative therapeutics aimed at difficult disease targets. Its platform allows clients to access native mass spectrometry without the need for sophisticated instrumentation or in-house expertise. This capability enables the study of complex protein assemblies and their interactions with other biological molecules, facilitating the development of drugs and biotherapeutics. OMass Therapeutics aims to provide a dynamic and collaborative environment for biotechnology and pharmaceutical clients to address challenging drug targets effectively.
Freeline Therapeutics
Series B in 2018
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.
SwanBio Therapeutics
Seed Round in 2018
SwanBio Therapeutics is dedicated to developing therapeutic technologies aimed at treating neurological diseases. The company specializes in creating and commercializing genetically defined therapies tailored for neurological disorders. Its innovative approach seeks to provide significant clinical efficacy, particularly for conditions such as Adrenomyeloneuropathy (AMN) and other related diseases, thereby supporting healthcare organizations in their efforts to improve patient outcomes.
Resolution Therapeutics
Seed Round in 2017
Resolution Therapeutics is a biopharmaceutical company focused on developing macrophage cell therapies aimed at treating chronic diseases, particularly end-stage liver diseases. The company investigates the potential of macrophages as therapeutic agents for conditions such as liver cirrhosis. Through its research and innovation, Resolution Therapeutics seeks to address the significant unmet regenerative therapeutic needs associated with chronic liver conditions, contributing to advancements in medical treatments for these ailments.
Autolus
Series C in 2017
Autolus Therapeutics is a biopharmaceutical company based in London, established in 2014 by Tim Funnell and Martin Pule. The company focuses on developing next-generation programmed T-cell therapies aimed at treating cancer. Its clinical-stage pipeline includes several candidates, such as Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8.
Nightstar Therapeutics
Series C in 2017
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Gyroscope
Seed Round in 2017
Gyroscope is a clinical-stage gene therapy company that specializes in developing treatments for retinal diseases, particularly focusing on Age-related Macular Degeneration (AMD), a major cause of blindness. The company leverages advancements in understanding the complement system's role in eye diseases and uses gene therapy as a therapeutic approach. Gyroscope's lead investigational therapy, GT005, is designed to be administered as a one-time treatment under the retina, aiming to restore balance to an overactive complement system by enhancing the production of the Complement Factor I protein. Currently, GT005 is undergoing evaluation in multiple clinical trials, including a Phase I/II trial named FOCUS and two Phase II trials called EXPLORE and HORIZON. Founded in 2016 in Stevenage, Herefordshire, by Andrew Lotery, David Kavanagh, and Peter Lachmann, Gyroscope seeks to provide innovative solutions for patients suffering from retinal diseases.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
Cambridge Epigenetix
Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Freeline Therapeutics
Series A in 2015
Freeline Therapeutics, established in 2015 and based in Stevenage, UK, is a clinical-stage biotechnology company specializing in the development of systemic adeno-associated virus (AAV) vector-mediated gene therapies. The company focuses on treating inherited, debilitating diseases by delivering functional copies of therapeutic genes into human liver cells, aiming to express functional proteins in the patient's bloodstream. Freeline's advanced product candidates include FLT180a for hemophilia B, FLT190 for Fabry disease, and FLT201 for Gaucher disease Type 1, all in various stages of clinical trials. Additionally, Freeline offers expertise in CMC process development, analytics, and AAV technologies.
Nightstar Therapeutics
Series B in 2015
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Blue Earth Diagnostics
Series B in 2015
Blue Earth Diagnostics Limited is a molecular imaging diagnostics company focused on developing and commercializing innovative positron emission tomography (PET) imaging agents for cancer management. The company specializes in detecting and localizing prostate cancer, particularly in men experiencing biochemical recurrence, through its flagship product, Axumin. Additionally, Blue Earth is advancing a range of prostate-specific membrane antigen (PSMA)-targeting radiohybrid agents, which are investigational theranostic compounds with potential applications in both imaging and treatment of prostate cancer. The company aims to address significant unmet medical needs in oncology, enhancing the efficiency of diagnosis and treatment for patients with prostate and brain cancers. Founded in 2013 and headquartered in Oxford, United Kingdom, Blue Earth Diagnostics also has offices in Burlington, Massachusetts, and Dublin, Ireland. It operates as a subsidiary of Bracco Imaging S.p.A.
Autolus
Series A in 2015
Autolus Therapeutics is a biopharmaceutical company based in London, established in 2014 by Tim Funnell and Martin Pule. The company focuses on developing next-generation programmed T-cell therapies aimed at treating cancer. Its clinical-stage pipeline includes several candidates, such as Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7, and AUTO8.
Cambridge Epigenetix
Series A in 2014
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.
Nightstar Therapeutics
Series A in 2014
Nightstar Therapeutics plc is a clinical-stage gene therapy company based in London, focused on developing innovative one-time treatments for rare inherited retinal diseases. The company’s lead product candidate, NSR-REP1, is currently in phase 3 clinical development for choroideremia, while NSR-RPGR is undergoing phase 2/3 trials for X-linked retinitis pigmentosa. Additionally, Nightstar is developing NSR-BEST1 and NSR-ABCA4, with the latter in preclinical development for Stargardt disease. Founded in 2017, Nightstar Therapeutics aims to address the unmet medical needs of patients suffering from these conditions.
Kesmalea Therapeutics
Kesmalea Therapeutics is a biotech startup dedicated to drug discovery, specifically focusing on the development of novel protein degraders. The company aims to create a new generation of oral medications by utilizing small molecules to modulate protein homeostasis. This innovative approach assists researchers in accelerating the identification of effective protein degraders and offers alternative therapeutic strategies for patients. By addressing challenging diseases that have historically lacked effective treatments, Kesmalea Therapeutics is committed to providing access to groundbreaking therapies that can significantly improve patient outcomes.
Kesmalea Therapeutics
Kesmalea Therapeutics is a biotech startup dedicated to drug discovery, specifically focusing on the development of novel protein degraders. The company aims to create a new generation of oral medications by utilizing small molecules to modulate protein homeostasis. This innovative approach assists researchers in accelerating the identification of effective protein degraders and offers alternative therapeutic strategies for patients. By addressing challenging diseases that have historically lacked effective treatments, Kesmalea Therapeutics is committed to providing access to groundbreaking therapies that can significantly improve patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.